Royalty Pharma plc Cash and Restricted Cash
Royalty Pharma plc (RPRX) had Cash and Restricted Cash of $811.99 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $811.99M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $586.39M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $618.70M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $938.94M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $811.99M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $586.39M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $618.70M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $938.94M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $631.91M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $1.09B 10-Q · filed 2026-05-06 | |
| 2024-12-31 | $929.03M 10-Q · filed 2026-08-05 | |
| 2024-09-30 | $950.05M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $1.76B 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $843.00M 10-Q · filed 2025-05-08 | |
| 2023-12-31 | $477.01M 10-K · filed 2026-02-11 | |
| 2023-09-30 | $936.45M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $2.17B 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $1.98B 10-Q · filed 2024-05-09 | |
| 2022-12-31 | $1.71B 10-K · filed 2026-02-11 | |
| 2022-09-30 | $991.63M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $2.11B 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $1.79B 10-Q · filed 2023-05-09 | |
| 2021-12-31 | $1.54B 10-K · filed 2025-02-12 | |
| 2021-09-30 | $1.80B 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $1.14B 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $708.81M 10-Q · filed 2022-05-05 | |
| 2020-12-31 | $1.01B 10-K · filed 2024-02-15 | |
| 2020-09-30 | $1.55B 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $2.32B 10-Q · filed 2021-08-11 | $2.44B 10-Q · filed 2020-08-12 |
| 2020-03-31 | $498.07M 10-Q · filed 2021-05-11 | |
| 2019-12-31 | $246.20M 10-K · filed 2023-02-15 | $283.68M 10-Q · filed 2020-08-12 |
| 2019-09-30 | $116.39M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $593.32M 10-Q · filed 2020-08-12 | |
| 2018-12-31 | $1.92B 10-K · filed 2022-02-15 | |
| 2017-12-31 | $1.38B 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |